Logo image
Evaluation of a digital health platform for reventing stroke in the Australian community: Study results for a multi-arm randomized controlled trial - Love Your Brain
Abstract   Open access   Peer reviewed

Evaluation of a digital health platform for reventing stroke in the Australian community: Study results for a multi-arm randomized controlled trial - Love Your Brain

Monique Kilkenny, Catherine Burns, Rosanne Freak-Poli, Tara Purvis, Muideen Olaiya, Dominique A Cadilhac, Amanda Thrift, Mark Nelson, Janet Bray, Jan Cameron, …
European stroke journal, Vol.11(Supplement 1), pp.i1006-i1006
12th European Stroke Organisation Conference , 12th (Maastricht, Netherlands, 06/05/2026–08/05/2026)
06/05/2026
url
LT75 - Evaluation of a digital health platform for preventing stroke in the Australian communityView
Published (Version of record) Open CC BY-NC V4.0

Related links

Metrics

1 Record Views

Abstract

Background and aims: The Love Your Brain digital platform was co-designed with people with lived experience to address the growing, worldwide demand for reliable information on how to prevent stroke. The platform comprises an online course and text messages to enhance knowledge, and identification and management of risk factors for stroke. Despite increasing availability of digital health interventions, few have been rigorously evaluated. We aimed to determine the efficacy of the digital platform to increase medical practitioner visits for assessment and/or management of cardiovascular risk factors. Methods: A prospective, single-blind, multi-arm randomized controlled trial (CTRN12625000124437), with intention-to-treat analysis. Eligible participants aged ≥45 years from across Australia, without a self-reported prior cardiovascular event, were randomly allocated 1:1:1 to receive either the experimental (online course or tailored text messages) or control intervention (limited general emails). The primary outcome is a self-reported visit to a medical practitioner for assessment and/or management of cardiovascular risk factors by 12-weeks. Secondary outcomes include change in stroke-related health knowledge, medication adherence, and adoption of risk-reducing health behaviours, assessed using validated online questionnaires. A sample size of 894 was estimated to provide 80% power to detect a 30% relative intervention effect with ≤10% attrition. Results: Overall, 941 participants were recruited by October 2025 with 12-weekfollow-up completed in January 2026. Results will be presented ESO conference. Conclusions: This randomized controlled trial will provide evidence on the efficacy of a novel co-designed digital health platform for assessing and managing stroke risk in the community.

Details

Logo image